Danish bank expects slow start to 2022 for Coloplast, lowers price target

Especially Coloplast's continence division is challenged, assesses Danish bank Jyske Bank, which is subsequently lowering its share price target for the medtech company ahead of its Q1 financial report.

Photo: Coloplast / PR

Danish bank Jyske bank is lowering its share price target for medtech company Coloplast prior to the release of its first quarter results on Jan. 25.

According to an analysis conducted by the bank, Coloplast has a slow start to 2022 ahead with a revenue of DKK 5.14bn (USD 783.9m) and an organic growth of 5.4 percent. As a comparison, Coloplast is expecting growth to land on 7 percent for the full year, but the consensus estimates read 5.3 percent.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs